NCT07191171View on ClinicalTrials.gov

Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

February 5, 2026

Study Completion Date

February 5, 2026

Conditions
Dysbiosis
Trial Locations (1)

67091

RECRUITING

Service de Pneumologie - CHU de Strasbourg - France, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER